Methods for making targeted protein toxins by sortase-mediated protein ligation

US2016102332A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2016102332-A1
Application numberUS-201514727017-A
CountryUS
Kind codeA1
Filing dateJun 1, 2015
Priority dateDec 3, 2012
Publication dateApr 14, 2016
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

We described novel methods for making targeted protein toxins by sortase-mediated protein ligation. The methods allow for a toxin and receptor-binding ligand to be ligated under mild conditions in vitro, following their expression and purification as single entities. The methods also provide a much more efficient way of making functional targeted fusion toxins compared to recombinant or chemical production of these structures.

First claim

Opening claim text (preview).

We claim: 1 . A method for making a protein toxin comprising a receptor-binding ligand, the method comprising the steps of: a. providing a protein toxin substrate and a C-terminal sortase-recognition motif optionally followed by an affinity epitope that is separated from the toxin by a linker; b. providing a targeting moiety comprising an N-terminal peptide; and c. contacting the protein toxin substrate of step (a) with the targeting moiety of step (b) with a sortase enzyme. 2 . The method of claim 1 , wherein the protein toxin substrate does not comprise its natural receptor binding domain or comprises a non-functional natural receptor binding domain. 3 . The method of claim 1 , wherein the targeting moiety is a receptor targeting ligand. 4 . The method of claim 1 , wherein the receptor is HER 2. 5 . The method of claim 3 , wherein the receptor targeting ligand is a HER2 antibody or HER2 AFFIBODY. 6 . The method of claim 1 , wherein the C-terminal sortase recognition motif is a sortase A recognition motif. 7 . The method of claim 6 , wherein the sortase A recognition motif is LPXTG (SEQ ID NO: 1), wherein X is any amino acid. 8 . The method of claim 7 , wherein the sortase A recognition motif is LPETGG (SEQ ID NO: 2). 9 . The method of claims 1 , wherein the C-terminal sortase recognition motif is a sortase B recognition motif. 10 . The method of claim 9 , wherein the sortase B recognition motif is NPQTN (SEQ ID NO: 3) or NPKTG (SEQ ID NO: 4). 11 . The method of claim 1 , wherein the affinity epitope is selected from a Histidine repeat (His 6 ) (SEQ ID NO: 5), maltose binding protein (MBP), protein A (ProtA), glutathione S-transferase (GST), calmodulin binding peptide (CBP), calmodulin, thioredoxin, Strep-tags, hemagglutinin, biotin, FLAG, V5, and c-myc. 12 . The method of claim 1 , wherein the linker comprises at least one Glycine-Serine repeat. 13 . The method of claim 12 , wherein the linker comprises 1-10 Glycine-Serine repeats (SEQ ID NO: 6). 14 . The method of claim 13 , wherein the linker comprises 3 or 4 Glycine-Serine repeats (SEQ ID NO: 7). 15 . The method of claim 1 , wherein the N-terminal peptide consists of more than two Glycine residues. 16 . The method of claim 15 , wherein the N-terminal peptide consists of 3-10 Glycine residues (SEQ ID NO: 8). 17 . The method of claim 16 , wherein the N-terminal peptide consists of five Glycine residues (SEQ ID NO: 9). 18 . The method of claim 1 , wherein the protein toxin is an anthrax toxin. 19 . The method of claim 1 , wherein the protein toxin is a diphtheria toxin. 20 . The method of claim 1 , further comprising the step of purifying the toxin that comprises a receptor-binding ligand. 21 . The method of claim 20 , wherein the step of purifying comprises sequential Ni 2+ -NTA affinity and size exclusion chromatography.

Assignees

Inventors

Classifications

  • C12P21/00Primary

    Preparation of peptides or proteins (single cell protein C12N1/00) · CPC title

  • Toxins · CPC title

  • containing a localisation/targetting motif · CPC title

  • containing a tag with affinity for a non-protein ligand · CPC title

  • containing a fusion with a toxin, e.g. diphteria toxin · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2016102332A1 cover?
We described novel methods for making targeted protein toxins by sortase-mediated protein ligation. The methods allow for a toxin and receptor-binding ligand to be ligated under mild conditions in vitro, following their expression and purification as single entities. The methods also provide a much more efficient way of making functional targeted fusion toxins compared to recombinant or chemica…
Who is the assignee on this patent?
Harvard College
What technology area does this patent fall under?
Primary CPC classification C12P21/00. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu Apr 14 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).